Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tirilazad treatment does not decrease early brain injury after transient focal ischemia in cats

R Takeshima1, J R Kirsch, R C Koehler

  • 1Department of Anesthesiology and Critical Care Medicine, Johns Hopkins Medical Institutions, Baltimore, Md.

Stroke
|March 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Improved Injury Detection Through Harmonizing Multi-Site Neuroimaging Data after Experimental TBI: A Translational Outcomes Project in NeuroTrauma (TOP-NT) Consortium Study.

bioRxiv : the preprint server for biology·2025
Same author

Improved injury detection through harmonizing multi-site neuroimaging data after experimental TBI: a Translational Outcomes Project in Neurotrauma consortium study.

Frontiers in neurology·2025
Same author

White matter apoptosis is increased by delayed hypothermia and rewarming in a neonatal piglet model of hypoxic ischemic encephalopathy.

Neuroscience·2016
Same author

Apparent diffusion coefficient scalars correlate with near-infrared spectroscopy markers of cerebrovascular autoregulation in neonates cooled for perinatal hypoxic-ischemic injury.

AJNR. American journal of neuroradiology·2014
Same author

Blood viscosity modulates tissue perfusion: sometimes and somewhere.

Transfusion alternatives in transfusion medicine : TATM·2009
Same author

Prostacyclin receptor deletion aggravates hippocampal neuronal loss after bilateral common carotid artery occlusion in mouse.

Neuroscience·2008
Same journal

Defining the Therapeutic Ceiling of Endovascular Thrombectomy in Large-Core Stroke: Beyond the Limits of ASPECTS.

Stroke·2026
Same journal

Adjunctive Normobaric Hyperoxia With Endovascular Thrombectomy for Acute Stroke at 6 to 24 Hours: A Phase IIb Randomized Trial.

Stroke·2026
Same journal

Management of Patients at Risk of Ischemic Stroke With Left Ventricular Systolic Dysfunction in the Absence of Intracardiac Thrombus: A Scientific Statement From the American Heart Association.

Stroke·2026
Same journal

Update on Rehabilitation After Stroke: Global Changes and the Continued Importance of Therapy Intensity, Dose, and Timing.

Stroke·2026
Same journal

ENTF Neuromodulation Yields Reduced Disability After Stroke: An Individual Participant-Level Data Meta-Analysis.

Stroke·2026
Same journal

Menopause and Its Implications for Stroke in Women.

Stroke·2026
See all related articles

Tirilazad mesylate did not improve electrophysiological recovery or reduce infarct volume in cats experiencing focal cerebral ischemia. This antioxidant showed no efficacy in this specific model of stroke, regardless of administration timing.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Ischemic Stroke Research

Background:

  • Transient focal cerebral ischemia can lead to significant neurological deficits.
  • Antioxidants are explored for their neuroprotective potential in stroke models.
  • Tirilazad mesylate is an antioxidant investigated for its effects on ischemia.

Purpose of the Study:

  • To evaluate the efficacy of tirilazad mesylate in improving electrophysiological recovery.
  • To determine if tirilazad mesylate decreases infarct volume after transient focal cerebral ischemia.
  • To test tirilazad mesylate's neuroprotective effects in a feline stroke model.

Main Methods:

  • Cats underwent 90 minutes of middle cerebral artery occlusion and carotid artery ligation, followed by 180 minutes of reperfusion.

Related Experiment Videos

  • Tirilazad mesylate was administered either at the onset of ischemia or at the conclusion of ischemia.
  • Infarct volume was quantified using 2,3,5-triphenyltetrazolium chloride staining; electrophysiological recovery was monitored.

    • Main Results:

    • Tirilazad mesylate administration did not alter blood flow distribution during ischemia or reperfusion.
    • Somatosensory evoked potentials showed no significant recovery differences among groups.
    • No significant differences in infarct volume were observed between tirilazad-treated groups and controls.

    Conclusions:

    • Tirilazad mesylate administered at the onset of ischemia or reperfusion did not reduce infarct volume in this feline model.
    • The study suggests tirilazad mesylate is not effective in ameliorating early reperfusion injury in this specific experimental setup.
    • Further research is needed to explore different dosing strategies or reperfusion durations for potential tirilazad mesylate efficacy.